Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (KR1020000070541) SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY

Office : Republic of Korea
Application Number: 1019997006786 Application Date: 28.07.1999
Publication Number: 1020000070541 Publication Date: 25.11.2000
Grant Number: 1003240580000 Grant Date: 16.02.2002
Publication Kind : B1
Prior PCT appl.: Application Number:PCTIB199701603 ; Publication Number:WO199832733 Click to see the data
IPC:
C07C 311/54
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
311
Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
50
Compounds containing any of the groups X being a hetero atom, Y being any atom
52
Y being a hetero atom
54
either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
Applicants: PFIZER INC.
디. 제이. 우드, 스피겔 알렌 제이화이자 인코포레이티드
Inventors: DOMBROSKI MARK ANTHONY
돔브로스키,마크,안토니
EGGLER JAMES FREDERICK
이글러,제임스,프레데릭
Agents: 주성민
김영
Priority Data: 60/036,979 29.01.1997 US
Title: (EN) SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY
(KO) 술포닐 우레아 유도체 및 인터루킨-1 활성 조절에서의 그의 용도
Abstract:
(EN)

A compound of formula (I) wherein R 1 and R 2 are as defined in the description, R 2 being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

© KIPO & WIPO 2007


(KO) 본 발명은 인간을 포함한 포유류에서의 뇌막염 및 난관염, 패혈성 쇼크, 파종성 혈관내 응집 및(또는) 성인 호흡 곤란 증후군, 급성 또는 만성 염증, 관절염, 담관염, 대장염, 뇌염, 심내막염, 사구체신염, 간염, 심근염, 췌장염, 심막염, 재관류 손상, 혈관염, 급성 및 지연성 과민증, 이식편 거부, 및 이식편 대 숙주 질환, 형태 I 진성 당뇨병 및 다발성 경화증을 비롯한 자가-면역 질환, 치근막 질환, 간질성 폐 섬유조직증식, 경변, 전신성 경화증, 켈로이드 형성, 자기분비 증식 인자로서 IL-1을 생성하는 종양, 악액질, 알츠하이머병, 타진 상해, 우울증, 아테롬성경화증 및 골다공증의 군으로 구성된 군으로부터 선택되는 상태의 치료에 유용한 화학식 I의 화합물에 관한 것이다.
Also published as:
CZPV1999-2575IS5099NO19993658SK98299TR1999/01816YUP-337/99
MXPA/a/1999/007030SG65991VN4111IL130855MA26468AR011093
EP0964849EP1270554EP1270565US6166064JP2000511200 CN1245490
CA2279186EA199900603DE000069722663DE000069729762PT964849PT1270565
NZ336248AU1998052340VN4111MYPI 98000291BG103597WO/1998/032733